landmark cardiology trials 1 The study evaluated 1,636 participants with ocular hypertension, defined as an intraocular pressure (IOP) of 24mm Hg to 32mm Hg in one eye and 21mm Hg to 34mm Hg in the other and no visual field (VF) loss or We are proud to have advanced medical knowledge in the cardiovascular arena with our landmark studies ONTARGET(R) and the parallel trial TRANSCEND(R). 1,2 Tresiba ® U-100 achieved the primary composite outcome, demonstrating no increased risk of MACE vs insulin glargine U-100. The EMMA study group looked at 49 total patients, but was not able to find any improvements with angioplasty at six months. CARDS. 2013; 36(9): 516-23. This entry was posted in Cardiology, Landmark Trials, New Clinical Trials and tagged antihypertensives, hypertension, MAPEC on July 19, 2013 by Sean P. 17, 2014 – The American Heart Association awarded its Clinical Research Prize for 2014 to Judith S. CARDS. CARMELINA is one of two cardiovascular outcome trials with the DPP-4 inhibitor Tradjenta. Jump to: navigation, search. We aimed to determine the most logical and practical mortality end-point in clinical trials of critically ill patients. The Landmark DECLARE-TIMI 58 Cardiovascular Outcomes Trial of FARXIGA in Patients with Type 2 Diabetes to Be Featured at AHA 2018 New data on cardiovascular effects of long-term BRILINTA use in WILMINGTON, Del. It has three main functions: Trials - Provides targeted access to standardized, structured study data. David Huang and Haney Mallemat answer some questions regarding the study and its implications. 95 Download. In response, 2 Minute Medicine™ presents 160+ authoritative, curated, and physician-written summaries of the key landmark trials in medicine: 2 Minute Medicine’s The Classics in Medicine: Summaries of the Landmark Trials. The results of the landmark ONTARGET(R) Trial have proven that telmisartan, brand name MICARDIS(R), a modern angiotensin II receptor blocker (ARB), is as protective as the current gold standard, ramipril, in reducing the risk of cardiovascular death, myocardial infarction, stroke, and hospitalisation for congestive heart failure in a broad COMPASS COMPASS is a randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in patients with coronary artery disease (CAD) or peripheral arterial disease (PAD). ,FACC,FESC Assos. registry on the efficacy of carotid stenting shows that the procedure is safe in patients who are at high risk for standard surgical therapy. It is not affiliated with or is an agent of, the Oxford Heart Centre, the John Radcliffe Hospital or the Oxford University Hospitals NHS Foundation Trust group. We have followed almost 50,000 telmisartan patients in clinical trials in the last 5 years, and now have experience from daily use of telmisartan summing up to 25 million patient years all over He was one of the authors in the landmark Acuity trial. J. Photo: NYU Langone Staff Landmark Papers In Most important trials and studies in cardiology are summarised in detail Summaries allow the reader to rapidly extract the results of major trials Each chapter written by a prominent international cardiologist in that particular field Concerns regarding the cardiovascular safety of thiazolidinediones were reported in earlier studies. ASCOT-BPLA. Data from the landmark HORIZONS-AMI clinical trial demonstrated that the administration of the anticoagulant medication bivalirudin enhanced survival compared to the use of heparin plus a The trial includes patients with high triglycerides and low HDL with diabetes with and without established cardiovascular disease, and will test whether K-877 reduces the occurrence of heart attacks, hospitalizations for unstable angina requiring unplanned revascularization, stroke, or death from cardiovascular causes. 2 million patients were eligible for inclusion in the systematic review. Today, the Cardiovascular research team streamlines the clinical research process through innovative study design, fit-for-purpose approaches, thoughtful analytics, and a commitment to rapid knowledge The trial includes patients with high triglycerides and low HDL with diabetes with and without established cardiovascular disease, and will test whether K-877 reduces the occurrence of heart attacks, hospitalizations for unstable angina requiring unplanned revascularization, stroke, or death from cardiovascular causes. Diabetes Care. Management of HER2-positive early-stage breast cancer Patients with HER2-positive early stage breast cancer generally warrant treatment with chemotherapy in addition to anti-HER2 agents. In the quest for the practice of evidence-based medicine, this is a landmark trial of sorts as these results will go a long way in clinical decision making in patients with stable CAD. Author: Boehringer Ingelheim. 0 out of 5 stars This repository of landmark clinical trials in cardiology, categorized by subspecialty, provides clinicians with summaries and links to original publications and related resources. Welcome to the website of the Women's Health Study (WHS) at Brigham and Women's Hospital and Harvard Medical School. Landmark Papers in Cardiovascular Medicine provides a thorough and wide-ranging analysis of core examples of novel research, clinical trials and seminal papers published in the medical literature that have paved the way for breakthroughs in the management of the entire spectrum of cardiovascular disease. Each chapter is written by a prominent international cardiologist in that particular field, making this book essential reading for all cardiologists and Some Landmark Trials … • United Kingdom Prospective Diabetes Study (UKPDS)=>UKPDS-PTM • Diabetes Control and Complications Trial (DCCT)=>EDIC • Diabetes Prevention Program (DPP)=>DPPOS • Action to Control Cardiovascular Risk in Diabetes (ACCORD)=>ACCORDION • Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Landmark Trial Compares Results of Invasive Strategy & Medical Therapy Alone for Stable Heart Disease The ISCHEMIA study, led by cardiologist Dr. Heart Issues and COVID AstraZeneca today announced positive results from the landmark Phase III DAPA-HF trial which showed that Farxiga (dapagliflozin) met the primary composite endpoint with a statistically-significant and clinically-meaningful reduction of cardiovascular death or the worsening of heart failure (defined as hospitalisation or an urgent heart failure visit), compared to placebo. Recent Publications in Cardiology. Findings of Largest Multi-Center Trial Released at ACC NEW YORK, NY, March 14, 2006 – Results from the largest-ever multi-center U. 25 Landmark Trials in Cardiology: 5th Edition. 4. Clinical Cardiology . This book elucidates the landmark trials in cardiology for diabetologists. These are presented at major meetings "Late Breaking Clinical Trials sessions", which last only 10 minutes, followed by 5 mins discussion. However, the optimal duration of follow-up for the determination of mortality endpoint in such trials is uncertain. From Wiki Journal Club < WikiJournalClub:List of landmark papers. DUBLIN, Ireland and BRIDGEWATER, N. The aim is to promote evidence-based medicine and to improve medical learning and education. All Saturday programming is from 8:00 AM – 1:15 PM ET. JAMA Netw Open 2021 Mar 23 In studies used to support FDA approval of 24 new cardiovascular drugs, Black people were consistently underrepresented. Document ID: PC-PH-101069 01/01/2020. Findings from a landmark study funded by the National Institutes of Health (NIH) support a key component of the new 2017 Hypertension Clinical Practice Guidelines announced by the American Heart Association (AHA) and the American College of Cardiology (ACC) at the annual AHA meeting in Anaheim, California. 5-10mg od Vs Metoprolol LOPRESSOR 50-200mg od Vs Amlodipine NORVASC 5-10mg od n CardioVascular, CardioRenal and Cardiometabolic medicine is increasingly evidence-based. 401-765-4100 Rhode Island Medicine, Inc. CHICAGO, Nov. VITAL researchers announce landmark trial findings. Heart Issues and COVIDThe US Centers for Disease Control (CDC) lists pre-existing serious heart conditions as a CARDIOLOGY LANDMARK TRIALS DAPA HF DAPAGLIFLOZIN NIK NIKAM MD Please subscribe to this NNN channel by clicking the subscribe button. 25 Landmark Trials in Cardiology 5th Edition: 1. Every year brings a series of landmark, game changing trials. 634918751162798750-Download slides CV risk and lipid management. 002) and 31% (P=0. Three ARS-Facilitated (3) Interactive Case Management Sessions: Moderated by Co-Chairs and Faculty. 1 The study evaluated 1,636 participants with ocular hypertension, defined as an intraocular pressure (IOP) of 24mm Hg to 32mm Hg in one eye and 21mm Hg to 34mm Hg in the other and no visual field (VF) loss or The Landmark DECLARE-TIMI 58 Cardiovascular Outcomes Trial of FARXIGA in Patients with Type 2 Diabetes to Be Featured at AHA 2018 - read this article along with other careers information, tips and advice on BioSpace FARXIGA Met Primary Endpoint in Landmark Phase III DAPA-HF Trial for the Treatment of Patients With Heart Failure DAPA-HF is the first heart failure outcomes trial with an SGLT2 inhibitor in The trial in question is the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, in which 76,693 men in the United States were randomly assigned to receive either annual Introduction Interventional ICU trials have followed up patients for variable duration. 10 In 2015, Boehringer Ingelheim and Eli Lilly and Company announced results from the landmark cardiovascular outcome trial EMPA-REG OUTCOME® with the SGLT2 inhibitor, empagliflozin, which reduced the relative risk of cardiovascular death by 38 percent in adults with . The problem is that the NIH and the SPRINT investigators have been working furiously— even prior to the presentation and publication of the full results— to sell the idea that the “landmark” trial offered powerful evidence that 120 was the new 140— that systolic blood pressure targets should be lowered for many patients to 120 mm Hg. Visualmed is a directory of landmark clinical trials in medicine. The intervention in this trial, which carefully adjusts the amount or type of blood pressure medication to achieve a target systolic pressure of 120 millimeters of mercury (mm Hg), reduced rates of cardiovascular events, such as heart attack and heart failure, as well as stroke, by almost a third and the risk of death by almost a quarter, as What. A new analysis suggests that women are under-represented in landmark heart failure clinical trials. 52 landmark EM articles for EM interns and junior residents. The median duration of follow-up was 2. 78 mmol/L) and reduced the risk of cardiovascular events. Given the holistic aspects of diagnosing and treating the cardiovascular patient, our in-house physicians work closely with leading cardiologists with whom they have long-standing relationships and who also serve as investigators, CEC, and DSMB members. There was a modest risk of serious adverse events. Each session is 1-hour. They besides have to hold a positive consequence on quality of life. However, only 21% of the study participants were women. The Heart Failure Trials app is designed by Dr. This landmark trial was begun in April 1993 to test the benefits and risks of low-dose aspirin and vitamin E in the primary prevention of cardiovascular disease and cancer in 39,876 U. Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure tis, aug 20, 2019 08:02 CET. 1 The secondary confirmatory endpoints compared rates and incidence of severe b Worldwide, most people with type 2 diabetes die of a cardiovascular event. Author information: (1)University of Chicago Medical Center, Chicago, IL, USA. 6736, you should be quite familiar with their Objectives, Methods, Results and Interpretation of those trials. S. women. The mean age at recruitment was 64 years, with the most common study population being trials of coronary artery disease (Table 1). Coming soon! Click Here > Vascular Surgery. Massimo Volpe, Allegra Battistoni, Giovanna Gallo, Roberta Coluccia, Raffaele De Caterina, Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk, High Blood Pressure & Cardiovascular Prevention, 10. Title / Author Type Language Date / Edition Publication; 1. Based on estimated cardiovascular event rates, we expect the CLEAR Outcomes trial to conclude in the second half of 2022. Landmark trials in preventive cardiology have utilized specific eligibility criteria to target individuals at risk for developing a future cardiovascular event. M. com has removed the direct-download link and offers this page for informational purposes only. The Ocular Hypertension Treatment Study (OHTS) This study from 2002 is one of the first to highlight central corneal thickness (CCT) as a significant structural risk factor for glaucoma. In FOURIER trial, inhibition of PCSK9 with evolocumab on a background of statin therapy-lowered LDL cholesterol levels to a median of 30 mg/DL (0. In summary, preliminary results from this landmark trial now provide robust scientific evidence favoring aggressive blood pressure control in patients with established cardiovascular disease or cardiovascular risks (without a history of diabetes or stroke). Imaging reveals new results from landmark stem cell trial for stroke. This trial is a landmark trial because it shows clear clinical benefit of perindopril on top of other preventive medications, on “hard” endpoints in a large, well-treated, patient population. Mar 29, 2021 | Cardiology; Are Important Clinical Trials Racially Balanced? Harlan M. (2011) 1(8) 1143 thiazide diuretic /b-blocker [20], although the European Society of Hypertension caution against the latter in patients with metabolic syndrome due to the increased risk of new-onset diabetes. –(BUSINESS WIRE)–New data from a sub-analysis of the landmark Phase III DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) trial showed that AstraZeneca’s FARXIGA(dapagliflozin) reduced the incidence of the primary composite endpoint of heart failure (HF) worsening or cardiovascular (CV) death compared to placebo, in patients with heart failure The trial, designed by leading experts on inflammatory heart disease, will test the cardioprotective properties of cannabidiol (CBD) for COVID-19 patients with a prior history of, or risk factors Read Free Land Mark Clinical Trials In Cardiology Home - ClinicalTrials. Evolution of Guidelines and Landmark Trials NHLBI = National Heart, Lung, and Blood Institute NCEP ATP = National Cholesterol Educ ation Panel Adult Treatment Panel AHA = American Heart Association ACC = American College of Cardiology IAS = International Atherosclerosis Society 10 NCEP ATP I 1988 Framingham MRFIT LRC-CPPT Coronary Drug Project 2018 Landmark Cardiology Trials, in Graphic Form — Six trials that will influence practice and research for years to come by Visualmed January 4, 2019 While 2019 is sure to be full of The first Edition of 25 Landmark Trials in Cardiology was created in 2005-06 in response to voiced frustrations among junior medicine, cardiology and off-service residents rotating through cardiology as well as non-cardiologist physicians who were overwhelmed by the sheer number of cardiology trials. com. Visit often to Top Clinical Trials. For instance, my attending staff asked me about choosing second anti-hyperglycemic therapy for diabetic patients. A principal investigator of a landmark women’s health study says initial results that linked hormone replacement therapy (HRT) to breast cancer and heart attacks were misleading and distorted for publicity. gov Landmark Clinical Trials The Society of Interventional Radiology Resident Fellow and Student Section (SIR RFS) is dedicated to Female Representation in Cardiovascular Clinical Trials. Over the course of their careers, many clinicians have seen HIV/AIDS progress from extremely high short-term mortality to chronic, long-term disease management. Host: NIK NIKAM, MD, MHA. Tsang W(1), Alter DA, Wijeysundera HC, Zhang T, Ko DT. 12 About MitraClip MitraClip received CE Mark in Europe in 2008 and was approved by the FDA in 2013 for primary MR prohibitive risk patients (patients not In the STRENGTH trial, which randomly assigned over 13,000 statin-treated patients with hypertriglyceridemia at high cardiovascular risk to a carboxylic acid formulation of omega-3 fatty acids (eicosapentaenoic acid and docosahexanoic acid) or corn oil, there was no difference after three years in the rate of a composite of major adverse cardiovascular events between the groups [ 22 ]. Clopidogrel + ASA vs ASA alone in cardiovascular disease. , of NYU Langone Medical Center “for exceptional leadership of landmark clinical trials profoundly impacting formulation of national practice guidelines for the management of ischemic heart disease. Collated and Commentary by Ashish Agrawal, MD. Antiplatelet data include the role of uninterrupted aspirin therapy during non-cardiac surgery and dual antiplatelet therapy following coronary artery bypass grafting. 1993;16:434-444. What do recent landmark, cardiovascular outcome trials evaluating PCSK9 inhibition in high risk patient populations teach us? Session PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease . “Depression is the leading cause of ill-health and disability worldwide, and treatment-resistant depression affects more than 100 million people,” Goldsmith said in a statement. ca, Jan, 2003 TRIAL / Regimen n= #pts, length, Publication Study baseline demographics/ Results (over study period) Abstract of entire trial Comments AASK 1 Ramipril ALTACE 2. ScienceDaily. ROPU RE-LY Smart video Related content MPR-PH The CRT 2021 Virtual Agenda At-A-Glance is your guide to our 10-week program. LANDMARK TRIALS IN STABLE CAD 1. By views, here are the top 10 trials on ACC. 25 Landmark Trials in Cardiology: 5th Edition Evidence for acute coronary syndrome (ACS) therapies; Antiplatelet therapy is the mainstay of treatment; aspirin and clopidogrel (CURE, COMMIT) improve mortality. A randomized trial of intensive versus standard blood-pressure control. Over 500 landmark trial summaries included! Support the The Classics Series™ by buying the paperback or e-book editions: These trials include the long-awaited ISCHEMIA (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches) and two trials, TWILIGHT (Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention) and AUGUSTUS (Antithrombotic Therapy After Acute Coronary Syndrome or PCI in Atrial Fibrillation) focusing on antiplatelet therapy post-stent in routine and special populations. 2004. 2005. Landmark Trial To Explore The Prevention Of Heart Disease In People Living With HIV Trial will evaluate if a daily dose of the statin, pitavastatin, can reduce the elevated risk of cardiovascular ICU Trials by ClinCalc is a quick pocket reference for both the novice and seasoned ICU clinician. Sessions on Cardiology and Infectious Diseases. The aim is to promote evidence-based medicine and to improve medical learning and education. Krumholz, MD, SM, reviewing Chen S and Li J. Slides: 2019 ESC guidelines on diabetes, pre-diabetes and cardiovascular diseases - Expert insights and rationale Slides (presentation) - Oct. A total of 325 landmark cardiovascular trials that enrolled more than 1. au Clinical trials traditionally aim to show a new treatment is superior to placebo or standard treatment, that is, superiority trials. CHICAGO, March 31 /PRNewswire/ -- The results of the landmark ONTARGET(TM) trial have demonstrated that MICARDIS(R) (telmisartan), a second-generation angiotensin II receptor blocker (ARB), is equally effective as the current standard, ramipril, in reducing the risk of cardiovascular death, myocardial infarction, stroke and hospitalization for The COAPT Trial met its primary endpoints and all 10 secondary endpoints as presented during the TCT cardiology meeting in Sept. METHODS • In this double-blind trial, investigators randomly assigned 2157 patients with acute heart failure to receive a continuous intravenous infusion of either ularitide at a dose of 15 ng per kilogram of body weight per minute or matching placebo for 48 hours, in addition to accepted therapy. 1. Address reprint requests to Dr. Huang, MD, MPH, Danish Malik, MD An interview with two experts Drs. The following brief summaries highlight some of the notable cardiology stories covered by MedPage Today thus far Landmark Trial to Examine Cardiovascular Treatment in HIV Patients Histology of 44-year-old man with myocardial infarction and HIV demonstrating typical features of MI. Dr. Here is our evolving list of landmark papers, organized by subspecialty. Over the past 30 years, the transition from print to digital media has contributed to an exponential increase in medical literature. David Majure, an advanced heart failure and transplant cardiologist at Washington Hospital Center. O. ” Cardiology. ACCOMPLISH ASCOT-BOLA HYVET ONTARGET, ONTARGET EDITORIAL VALUE Trial Enrichment Trials in Hypertension AASK ACCF/AHA 2011 HTN in Elderly ALLHAT HOPE and Micro-HOPE HOPE Ambulatory vs Office blood pressure measurement PROGRESS TRIAL PROGRESS TRIAL 3 yr later RENAAL Study In addition to the “landmark” clinical trials, the aggregated evidence from smaller pragmatic trials, mechanistic trials, research on the delivery of health care, and economic and policy analyses must be woven into a coherent plan for patients, providers, and payers. What. For a shorter list of very high-priority landmark papers, see WikiJournalClub:High-priority articles. Invest. Recent findings: The CLEAR Wisdom trial examined the safety and efficacy of adding bempedoic acid to maximally tolerated statin for reducing low-density lipoprotein New preventative cardiology data include trials of liraglutide, empagliflozin, PCSK9 inhibitors (evolocumab and bococizumab), inclisiran, and anacetrapib. today announced new findings from the landmark IMPROVE HF (Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting) trial, which showed equivalent improvements in the care of heart failure patients across all races and ethnicities when evidence-based, performance improvement interventions were applied in outpatient settings. edu. , Nov. The following medical conditions affect the structure and function of the heart and blood vessels. 7, 2019 - Prof Francesco Cosentino, MD, Stockholm, Sweden - CME symposium held during ESC 2019 The ACCOMPLSH trial evaluated amlodipine (calcium channel blocker) vs. Summaries of landmark clinical trials. Welcome. Lincolnshire, IL, June 28, 2004 – In the July 2004 issue of Diabetes Care, researchers published the study design and baseline characteristics of patients enrolled in the landmark PROspective PioglitAzone Clinical Trial In MacroVascular Events Study (PROactive). An updated version of STARTRIALTM was launched in October 2008. Critical Care Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Landmark SPYRAL HTN-OFF MED Pivotal Trial Shows Superiority for Renal Denervation in Patients with High Blood Pressure Compared to Sham Procedure American College of Cardiology together with The problem is that the NIH and the SPRINT investigators have been working furiously— even prior to the presentation and publication of the full results— to sell the idea that the “landmark” trial offered powerful evidence that 120 was the new 140— that systolic blood pressure targets should be lowered for many patients to 120 mm Hg. The landmark DAPA-HF trial has altered standard care in patients with HFrEF. The selection criteria for consideration for inclusion are randomised trial design, clinical outcome as a primary endpoint, and publication in one of ten high-ranking medical journals, with a print publication date within the last 5 years. RECORD was a study to elucidate the cardiovascular safety of rosiglitazone compared to combination therapy of sulfonylurea + metformin (standard of care) Thiazolidinediones are associated with an increased risk for heart failure (fluid retention Guilford Pharmaceuticals announced two landmark trials that will advance the field of interventional cardiology by attempting to determine the optimal therapeutic regimen for high-risk patients undergoing percutaneous coronary intervention (PCI). In 2015, Boehringer Ingelheim and Eli Lilly and Company announced results from the landmark cardiovascular outcome trial EMPA-REG OUTCOME ® with the SGLT2 inhibitor empagliflozin, which reduced the relative risk of cardiovascular death by 38 percent in adults with type 2 diabetes and established cardiovascular disease, on top of standard of care. *FREE* shipping on qualifying offers. gov Landmark Clinical Trials The Society of Interventional Radiology Resident Fellow and Student Section (SIR RFS) is dedicated to Visualmed is a directory of landmark clinical trials in medicine. Correspondence to Professor Dominic Y Leung, Cardiology, University of New South Wales, Liverpool Hospital, Sydney, NSW 2052, Australia; d. The trial, designed by leading experts on inflammatory heart disease, will test the cardioprotective properties of cannabidiol (CBD) for COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease (CVD). Created by physicians, the app help physicians/medical students easily find any landmark trials, and how they are related to the most contemporary consensus. 2015;4(4):109-10 Atrial Fibrillation (AF) is associated with increased risk for stroke and reduced survival. Landmark Trials in Hypertension. More than 5,000 patients with type 2 diabetes studied. Later, the staff mentioned TECOS, LEADER, and ORIGIN trial to me. clinicaltrials. Landmark Trial Compares Results of Invasive Strategy & Medical Therapy Alone for Stable Heart Disease A study finds that medical therapy alone produces similar results as more aggressive approaches. He is a National Instructor for Covidien to train doctors in doing ablation therapy. 001) lower in the enalapril group The NIDDK funded the landmark Diabetes Control and Complications Trial (DCCT) to see if people with type 1 diabetes who kept their blood glucose levels as close to normal as safely possible with intensive diabetes treatment (three or more shots of insulin per day or an insulin pump with self-monitoring of blood glucose at least four times per day) could slow the development of eye, kidney, and George Goldsmith, chairman and co-founder, expressed excitement for the beginning of the landmark trial. Landmark Clinical Trials: Vascular Procedures. Contents. The primary efficacy end-point was the composite of cardiovascular death. Cardiovascular disease (CVD) is a major slayer and hence it is an of import mark country for pharmaceutical intercession. Antihypertensives: Landmark & Recent Trials Prepared by: Brent Jensen BSP for www. Introduction • Stable Ischemic Heart Disease is most commonly (?) caused by atheromatous plaque that gradually narrows one or more of the epicardial coronary arteries. leung{at}unsw. Some were first presented in 2018 or even earlier, but trial updates were presented in 2019 and highly viewed. The 4S trial conclusively determined that statin therapy was a safe and more effective treatment choice in lowering serum LDL cholesterol than other lipid-lowering agents. To provide a resource for evidence-based Emergency Medical education, this list of must-read landmark articles was created to supplement the Emergency Medicine (EM) internship year of training. Asthma Landmark Trials. D. Medical Center Dr. There Amgen Inc. The landmark method was introduced in 1983, in the first year of the Journal of Clinical Oncology (JCO) by Anderson et al, 1 in an article addressing the issue of bias in the analysis of survival of “responders” and “nonresponders,” a popular analysis in oncology. Founded by internal medicine residents at Georgetown and Stanford. Landmark Trials in Cardiology in 2017-Celebrating 40 Years of Angioplasty. Recent Landmark Trials in Cardiology Newer Evidence in Atrial Fibrillation Management Volume 4, Oct 2015 Gagandeep Singh Wander DM, Gurgaon, India J Clin Prev Cardiol. (2019, September 18). Gabor Gyenes. 2004. Cardiovascular Risk Reduction in T2DM: Applying Trial Data in Cardiology Practice will explore the burden of CVD in patients with T2DM, and outline the results from cardiovascular outcomes trials exploring the benefits and risks of antihyperglycemic agents in reducing CVD in patients with T2DM. The EMMA study group looked at 49 total patients, but was not able to find any improvements with angioplasty at six months. FOURIER (Further Cardiovascular OUtcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk), a multinational Phase 3 randomized, double-blind, placebo-controlled trial, is designed to Landmark Outcomes Study Shows That Repatha® (Evolocumab) Decreases LDL-C To Unprecedented Low Levels And Reduces Risk Of Cardiovascular Events With No New Safety Issues Repatha Significantly Reduces Risk of Hard Major Adverse Cardiovascular Events by 20 Percent Landmark Lipid-Lowering Trials in the Primary Prevention of Cardiovascular Disease. Learn vocabulary, terms, and more with flashcards, games, and other study tools. The reduction in the worsening of heart failure-related events was accompanied by a significant reduction in CV death that was not significantly different for those with or without diabetes. 2 million patients were eligible for inclusion in the systematic review. Headline-making developments for 2018 included new guidelines and landmark trials. Worldwide, most people with type 2 diabetes die of a cardiovascular event. Leuven Belgium, 2019, November 27th – a significant milestone has been reached for a landmark study into the use of short duration dual anti-platelet therapy (DAPT) in high-bleeding-risk (HBR) patients following stenting procedures, with patient recruitment just completed. 2019 Oct 24;381[17]:1609-20) and the landmark PARADIGM-HF trial that established sacubitril/valsartan as NOTE: Landmark Trials are those trials which are of substantive influence on the clinical practice of cardiovascular medicine. Landmark Trials in Renal Artery Stenosis A few small randomized trials began in the late 1990’s to determine a competitive advantage of angioplasty for RAS. 2. It was shown that the six and 12-month mortality rates were 40% (P=0. It is the leading cause of end-stage renal disease (ESRD) worldwide, accounting for 42% of all patients on renal replacement therapy (RRT) in the USA [ 2 ]. ASCOT-BPLA. Methods We performed a retrospective analysis of prospectively collected We are proud to have advanced medical knowledge in the cardiovascular arena with our landmark studies ONTARGET(R) and the parallel trial TRANSCEND(R). Female Representation in Cardiovascular Clinical Trials. In addition to this a literature search of PubMed, Medline, Cochrane library and Embase was completed including the terms “acute coronary syndrome”, “atrial fibrillation”, “coronary prevention”, “electrophysiology”, “heart failure” and “interventional cardiology”. Landmark Trials. Landmark Papers in Cardiovascular Medicine provides a detailed summary of the most important trials and studies in cardiology, which have paved the way for breakthroughs in the clinical management of the entire spectrum of cardiovascular disease. Hochman, M. Kane. D. Clinical trial methods that have been adapted or developed by NHLBI clinical trials have been widely accepted in research for COPD and related conditions. Others involved in the study claim the findings were merely misunderstood. there is a rapid review of the must know points about each of these clinical trials that made an impact on determining 25 Landmark Trials in Cardiology By Skyscape $24. 2005. Yancy, based on a new analysis of data collected from both the recent PARAGON-HF trial of sacubitril/valsartan in patients with HFpEF and ejection fractions of 45% or higher (N Engl J Med. The department of cardiology is committed to cutting edge basic science and clinical research. Landmark Papers in Cardiology provides a detailed summary of the most important trials and studies in cardiology, which have paved the way for breakthroughs in the clinical management of the entire spectrum of cardiovascular disease. ACS Trials also includes an extensive cardiology medical calculator, with instant access to 30 of the most commonly used formulas and risk stratification models in acute coronary syndromes Landmark Trials in Critical Care. In 2015, Boehringer Ingelheim and Eli Lilly and Company announced results from the landmark cardiovascular outcome trial EMPA-REG OUTCOME ® with the SGLT2 inhibitor empagliflozin. 1) There are three landmark cardiovascular outcome trials of SGLT2 inhibitors that have led to plenty of excitement in the fields of cardiology and diabetes – EMPA-REG OUTCOME (empaglifozin), CANVAS (canagliflozin) and DECLARE-TIMI 58 (dapagliflozin). 2 years. N=2016 patients, age>50, history or risk factors of cardiovascular disease, s/p That premise should now go out the window, urged Dr. Speaker Philippe Gabriel Steg The Classics in Medicine: Summaries of the Landmark Trials: Includes 160+ study summaries from the following fields: General Medicine and Chronic Disease, Cardiology, Critical and Emergent Care, Endocrinology, Gastroenterology, Hematology and Oncology, Imaging, Infectious Disease, Nephrology, Neurology, Pediatrics, Psychiatry, Pulmonology, and The Heart Outcomes Prevention Evaluation (HOPE) study was a landmark study employing the angiotensin-converting enzyme (ACE) inhibitor ramipril in a patient population predestined for vascular Diabetic nephropathy (DN) is estimated to affect one-third of individuals with DM and is associated with considerable cardiovascular morbidity and mortality. As a student of Phar. Clinical Trials in Cardiology/Vascular Diseases. David Majure, an advanced heart failure and transplant cardiologist at Washington Hospital Center. Trial summaries contain: • Target disease,… The ACCORD blood pressure trial is the largest clinical trial to test the effect on cardiovascular disease of systolic blood pressure (the top number in a blood pressure reading) below 120 mmHg, which is considered normal. Click on a condition below to find clinical trials actively recruiting research study volunteers in your area. Judith S. The app’s content is extensive, reviewing over fifty trials ranging from landmark beta blocker trials like CONSENSUS to more recent studies evaluating device therapy like BLOCK-HF. Bhatt, MD, MPH, FACC Senior Associate Editor, Clinical Trials and News, ACC. General Cardiology, Interventional, EP, Imaging, and much more! Click Here > CT Surgery. Results of Landmark CV Outcome Trials and European Guidelines Applied to the Front Lines of Cardiovascular Care—Best Practice Pathways for Reducing ASCVD Risk in High Risk Patients. Amlodipine vs atenolol in hypertension. Retrieved December 23, 2020 from www Landmark Study Shows Treatment with Abbott's MitraClip® is Superior to Medical Therapy for Advanced Heart Failure Patients with Significant Secondary Mitral Regurgitation - The COAPT trial met both the primary safety and efficacy endpoints and all secondary endpoints, including reducing all-cause mortality through two years The RE-LY Trial: A Landmark Study in Cardiology. This app does not replace the original manuscript of these landmark trials – instead, it serves as a fast reference and learning tool for some of the most important critical care trials over a wide range of specialties. Newer P2Y12 inhibitors improve mortality further (TRITON-TIMI-38, PLATO), but possibly not those conservatively managed (TRILOGY-ACS). These trials and studies have guided our knowledge about the disease and our approach to the diagnosis and treatment of a pulmonary embolism. It let users access summaries of important randomized controlled trials on the go. 11, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) announced today the results from the subgroup of 3,146 patients randomized in the United States within the global Vascepa ® (icosapent ethyl) cardiovascular (CV) outcomes trial, REDUCE-IT ®. Worldwide, most people with type 2 diabetes die of a cardiovascular event. , Ann Arbor, MI 48109-0366. The mean age at recruitment was 64 years, with the most common study population being trials of coronary artery disease (Table 1). org for 2019, in alphabetical order. 10 In 2015, Boehringer Ingelheim and Eli Lilly and Company announced results from the landmark cardiovascular outcome trial EMPA-REG OUTCOME ® with the SGLT2 inhibitor, empagliflozin, which reduced the relative risk of cardiovascular death by 38 percent in adults with Landmark Papers in Cardiovascular Medicine provides a thorough and wide-ranging analysis of core examples of novel research, clinical trials and seminal papers published in the medical literature that have paved the way for breakthroughs in the management of the entire spectrum of cardiovascular disease. I searched in the internet, found an overwhelming number of clinical trials, and didn't know what to pick for answer. The American Heart Journal article reviews the role of diabetes and anemia in cardiovascular disease among patients with CKD and provides the rationale for designing and conducting TREAT, which is an international 4,000 patient, multicenter, randomized, double-blind, placebo-controlled trial. 16 In 2015, Boehringer Ingelheim and Eli Lilly and Company announced results from the landmark cardiovascular outcome trial EMPA-REG OUTCOME ® with the SGLT2 inhibitor, empagliflozin, which reduced the relative risk of cardiovascular death by 38 percent in adults with The Scandinavian Simvastatin Survival Study (also known as the 4S study), was a multicentre, randomized, double-blind, placebo-controlled clinical trial, which provided the initial data that supported the use of the cholesterol-lowering drug, simvastatin, in people with a moderately raised cholesterol and coronary heart disease (CHD); that is people who had previously had a heart attack or angina. Read Free Land Mark Clinical Trials In Cardiology Home - ClinicalTrials. Trials under the heading of Enrichment are to supplement information. The majority Driven by a landmark cardiovascular outcomes trial that could spell blockbuster sales for its fish-oil derivative, Vascepa, Amarin has been a darling for pharma M&A speculators. Evolution of Guidelines and Landmark Trials NHLBI = National Heart, Lung, and Blood Institute NCEP ATP = National Cholesterol Educ ation Panel Adult Treatment Panel AHA = American Heart Association ACC = American College of Cardiology IAS = International Atherosclerosis Society 9 NCEP ATP I 1988 Framingham MRFIT LRC-CPPT Coronary Drug Project 25 Landmark Trials in Cardiology: 5th Edition [Gyenes, Gabor, Butler, Craig, Welsh, Robert] on Amazon. Clinical Cardiology, 2013. Findings from a landmark study funded by the National Institutes of Health (NIH) support a key component of the new 2017 Hypertension Clinical Practice Guidelines announced by the American Heart Association (AHA) and the American College of Cardiology (ACC) at the annual AHA meeting in Anaheim, California. Drugs developed for CVD demand to be effectual and have as few side effects as possible. WikiJournalClub:List of landmark papers/Cardiology. ,D. Key cardiology trials in evidence based medicine - click on a trial for more information or a topic above for a summary; Topic Therapy group Therapy Trial; Acute coronary syndromes: ACE inhibitors: Captopril: ISIS-4: Lisinopril: GISSI-3: Aldosterone antagonists: Eplerenone: EPHESUS: Anti-platelet therapy: Aspirin: ISIS-2, CURRENT-OASIS-7 Landmark Papers in Cardiology provides a detailed summary of the most important trials and studies in cardiology, which have paved the way for breakthroughs in the clinical management of the The Online Edition of The Classics Series™ includes The Classics in Medicine™ textbook and all deep-dive sub-specialty books, such as The Classics in Cardiology™, Classics in Radiology™, etc. “It is a huge unmet need and the trial will teach us more Presenting a total of 15 studies at this week’s American College of Cardiology’s Annual Scientific Sessions, researchers from the University of Rochester Medical Center continue to mine valuable information from the milestone MADIT-CRT trial, furthering our knowledge of heart failure and related disorders, which affect millions worldwide. rxfiles. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial, also known as ALLHAT, was a randomized, double-blind, active-controlled study comparing at the same time, four different classes of antihypertensive drugs with the rate of coronary heart disease (CHD) events in ‘high-risk’ people with hypertension. 25 Landmark Trials in Cardiology, 978-3-330-05363-2, The first Edition of this book was created in 2005-06 in response to voiced frustrations among junior medicine, cardiology and off-service residents rotating through cardiology as well as non-cardiologist physicians who were overwhelmed by the sheer number of cardiology trials. CARDIOLOGY LANDMARK TRIALS | ISCHEMIA TRIAL BY NIK NIKAM MDPlease subscribe to this NNN channel by clicking the subscribe button. The results of clinical trials presented at major international cardiology meetings in 2019 were reviewed. An algorithm of clinical trials is displayed according to type of Adjunct pharmacological therapy of ACS. The American Heart Journal article reviews the role of diabetes and anemia in cardiovascular disease among patients with CKD and provides the rationale for designing and conducting TREAT, which is an international 4,000 patient, multicenter, randomized, double-blind, placebo-controlled trial. Payal Kohli The ProCESS Trial: A Landmark Study in Sepsis Management 6/9/2014 Haney A. Clopidogrel + ASA vs ASA alone in cardiovascular disease. Landmark Trials in Renal Artery Stenosis A few small randomized trials began in the late 1990’s to determine a competitive advantage of angioplasty for RAS. The major trials and studies causing most impact are mentioned in this chapter. Now, after The trial, designed by leading experts on inflammatory heart disease, will test the cardioprotective properties of cannabidiol (CBD) for COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease (CVD). DAPA-HF is the first heart failure outcomes trial with an SGLT2 inhibitor in patients with and without type-2 diabetes “the intervention in this trial, which carefully adjusts the amount or type of blood pressure medication to achieve a target systolic pressure of 120 millimeters of mercury (mm Hg), reduced rates of cardiovascular events, such as heart attack and heart failure, as well as stroke, by almost a third and the risk of death by almost a quarter, as The Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) trial was the first landmark paper to evaluate the effect of enalapril on mortality, compared to placebo, in patients with severe congestive HFrEF . Pittsburgh, PA 15213 and With each new addition of “25 landmark trials” we continue to comb through the cardiovascular literature for robust trials that consolidate mature lines of evidence and ultimately persuade us DAPA-HF So the first one I want to talk about is the DAPA-HF trial, one of the real landmark trials in heart failure. Cardiovascular medicine accounts for the fastest growing area of clinical research. The majority Access a concise compilation of published randomised trials in the field of interventional cardiology in the PCR Trials book. section 4 (PPTX 579KB) Worldwide, most people with type 2 diabetes die of a cardiovascular event. Amlodipine vs atenolol in hypertension. Akshyaya Pradhan Department of Cardiology, King George's Medical University, Lucknow, Uttar Pradesh, India. Adikesava Naidu M. Cardiology. Pitt at the Division of Cardiology, University of Michigan Medical Center, 3910 Taubman, 1500 E. Deepak L. There have been various trials and studies since the discovery of PE. This prespecified REDUCE-IT subgroup The trial, designed by leading experts on inflammatory heart disease, will test the cardioprotective properties of cannabidiol (CBD) for COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease (CVD). PROSEVA Trial – Prone Positioning in Severe ARDS New Late-Breaking Analyses from Landmark COAPT Trial Show Benefits of Abbott's MitraClip Device March 17, 2019 New data presented and simultaneously published in the Journal of the American College of Cardiology show treatment with MitraClip resulted in significant and sustained long-term quality-of-life improvements compared to medical therapy Driven by a landmark cardiovascular outcomes trial that could spell blockbuster sales for its fish-oil derivative, Vascepa, Amarin has been a darling for pharma M&A speculators. Professor Deepak L. We have many ongoing trials, NIH grants, and renowned labs within our institution. 1007/s40292-017-0213-4, 24, 3, (331-339), (2017). Purpose of review: At the 2019 American College of Cardiology annual scientific sessions, major randomized clinical trials in cardiovascular disease (CVD) prevention were presented. University of Texas Health Science Center at Houston. In the PARADIGM-HF trial, the use of sacubitril-valsartan reduced heart failure hospitalisations as well as cardiovascular death by 20% compared to enalapril. The landmark ISCHEMIA trial rattled the cardiology world with its message that clinical outcomes weren’t significantly better with a routine initial invasive strategy than with medical therapy alone in patients with stable coronary artery disease and moderate or severe myocardial ischemia on noninvasive testing. The impact of cardiovascular disease prevalence on women's enrollment in landmark randomized cardiovascular trials: a systematic review. Thanks to your commitment to taking the study capsules and filling out the health questionnaires, we now have the results of the largest and longest randomized trial of daily high-dose vitamin D (vitamin D3 [cholecalciferol], 2000 IU) and omega-3 fatty acid supplementation (Omacor® fish oil, 1 gram) for the prevention of cancer and One of the major accomplishments of NHLBI-sponsored landmark trials is the influence on standard procedures for conducting COPD clinical trials. Landmark Lipid-Lowering Trials in the Primary Prevention of Cardiovascular Disease. gov . (Nasdaq:AMGN), the world's largest biotechnology company, today announced that the company has initiated a landmark trial to evaluate the impact of treating anemia on cardiovascular outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes. Other investigators Radcliffe Cardiology is part of Radcliffe Medical Media, an independent publisher and the Radcliffe Group Ltd. The Heart Failure Trials app is designed by Dr. 1-3 For a comprehensive look at inclusion and exclusion criteria, and endpoint information, please visit www. Including studies where there has either been a major publication of diabetes data, or where there was an important diabetes sub-group within the main article, each chapter lists the key clinical trials, and includes a commentary and ‘take-home’ points on each trial. The publication of the UGDP trial in 1970 raised concerns for the first time on the safety of SUs. These results will obviously influence future hypertension guidelines and clinical practice. The New Adjuvant Trial with LEE study is an ongoing (NCT03701334) phase III trial of 3-year of ribociclib added to 5 years of standard ET . The Landmark Clinical Trial Review was specifically developed to help pull together some of the most important, "practice-changing" clinical trials to make it easy for you to follow and understand. Moreover, it provided the largest reduction in cardiovascular mortalities, and the benefit was witnessed in all age groups. Hochman, finds that medical therapy alone produces similar results as more aggressive approaches. Landmark Trials Trials Assessing the Prevention of VTE. Google Scholar DEVOTE is the first safety outcomes trial evaluating the noninferiority in risk of major adverse cardiovascular events (MACE a) with Tresiba ® U-100 vs insulin glargine U-100. A Clinically Oriented Review of the Landmark Clinical Trials Comparing Warfarin and Aspirin to Novel Oral Anticoagulants in Atrial Fibrillation Brian L Henry, Jacob C Jentzer, Jonathan E Holtz, Chirag A Chauhan, Aref M Rahman* University of Pittsburgh Medical Center, Heart and Vascular Institute, 200 Lothrop St. org. Now, after The 3-year landmark analysis from the ReCre8 multi-center, randomized, all-comer trial assessing noninferiority of polymer-free amphilimus-eluting stents (PF-AES) compared to permanent polymer zotarolimus-eluting stents (PP-ZES) were presented at CRT 2021. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Do not delay accelerating your knowledge and ability to make evidence-based medical decisions. The app’s content is extensive, reviewing over fifty trials ranging from landmark beta blocker trials like CONSENSUS to more recent studies evaluating device therapy like BLOCK-HF. I have a problem with searching and recognizing remarkable trials related to my patients. Asthma Landmark Trials. Dr. Thus, I Impact of recent landmark clinical trials on hypertension treatment Review: Clinical Trial Outcomes future science group Clin. Rationale : In patients WITHOUT a history of diabetes or stroke, does intensive blood pressure control improve outcomes? Intensive blood pressure control improves cardiovascular outcomes in patients at a high risk for CVD. Cardiology & Heart Surgery Highlights, Cardiology & Heart Surgery Highlights 2019–2020 Download Print Version (PDF) The DCRI has built on this history by conducting landmark clinical trials and making discoveries that have changed the field of cardiology. 2018 and published in the New England Journal of Medicine. Host: NIK NIKAM, MD, MHA Landmark Clinical Trials - Cardiology. Bhatt, MD, MPH, FACC, FESC – Program Chair Start studying Cardiology Landmark Clinical Trials. S. IMP Landmark Clinical Trials The RFS Landmark Clinical Trials Database The Society of Interventional Radiology Resident Fellow and Student Section (SIR RFS) is dedicated to supporting IR trainees’ clinical knowledge by providing information on landmark clinical trials transforming the field of IR. Johnson AE, Eid SM, Winner L, Hody R, Simmons T, Sampedro A, Sylvester C, Parahk K. The Ocular Hypertension Treatment Study (OHTS) This study from 2002 is one of the first to highlight central corneal thickness (CCT) as a significant structural risk factor for glaucoma. Including studies performed on patients with diabetes or pre-diabetes, each chapter lists the key clinical trials, and includes a commentary and ‘take-home’ points on each trial. The landmark DECLARE-TIMI 58 cardiovascular outcomes trial of Farxiga in patients with type-2 diabetes to be featured at AHA 2018 PUBLISHED 1 November 2018 New data on cardiovascular effects of long-term Brilinta use in patients with a history of heart attack The Heart and Vascular Center, through its LeBauer-Brodie Center for Cardiovascular Research and Education, has remained a consistent leader in the landmark clinical trials testing the new strategies, drugs, and devices that have defined best practice. It let users access summaries of important randomized controlled trials on the go. A total of 325 landmark cardiovascular trials that enrolled more than 1. The registry, an FDA-required post-approval study, known as CAPTURE (Carotid ACCULINK/ACCUNET Post Approval Trial to Loyola University Medical Center is the only Chicago hospital participating in a landmark clinical trial of an artificial aortic heart valve that does not require open heart surgery. Professor in Cardiology, Osmania Medical College/OGH, Hyderabad. Mallemat, MD, David T. Among those without CVD, it is important to identify low‐risk, moderate‐risk, and high‐risk individuals to tailor therapy. Dr. The trial, designed by leading experts on inflammatory heart disease, will test the cardioprotective properties of cannabidiol (CBD) for COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease (CVD). Please see the links below for more information on the research going on in the department of Cardiovascular Medicine. hydrochlorothiazide (diuretic) added to an ACE inhibitor (benzapril) in patients with hypertension and high cardiovascular ‎* Promotional Period: Limited time offer!! HeartEvidence reviews the top trials in cardiology. We have followed almost 50,000 telmisartan patients in clinical trials in the last 5 years, and now have experience from daily use of telmisartan summing up to 25 million patient years all over MINNEAPOLIS – Medtronic, Inc. The trial reported that tolbutamide, a first-generation SU, might be associated with an increased risk of CV death. Several landmark trials in the 1980s and 1990s (SOLVD [Studies of Left Ventricular Dysfunction], MERIT-HF [Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure], EMPHASIS-HF [Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure], and TOPCAT [Treatment of Preserved Cardiac Function Heart Failure The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from This book elucidates the landmark trials in diabetes for cardiologists. Lowering blood pressure to normal levels — below currently recommended levels — did not significantly reduce the combined risk of fatal or nonfatal cardiovascular disease events in adults with type 2 diabetes who were at especially high risk for cardiovascular disease events, according to new results from the landmark Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial. Lieber has a significant interest in vein disease which is the most underdiagnosed disease in cardiology, yet the 3rd most disabling. 68 Cumberland Street, Suite 205 Woonsocket, RI, 02895 401-765-4100 View Profile Landmark papers in cardiovascular medicine. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. The trials were conducted at 536 sites in 33 countries, including Canada, Mexico, Russian Federation, Ukraine, Turkey, India, South Africa, Japan, Hong Kong, multiple European countries, Argentina, Reassurance from landmark trials on cardiac safety of SUs. So we know that SGLT2 inhibitors in randomised controlled trials in patients Landmark papers are highly influential papers that have substantially changed the practice of medicine or provided the missing evidence to support current practices. Washington, DC, June 12, 2006 – New analyses from the landmark PROactive Study found that ACTOS® (pioglitazone HCl), an oral antidiabetic medication, significantly reduced the occurrence of major adverse cardiovascular events (MACE) such as heart attacks (excluding silent heart attacks), nonfatal stroke, acute coronary syndrome (ACS) and cardiovascular death in high-risk patients with type With respect to the primary endpoint of the trial, approximately 50 patients must be treated for 4 years to prevent one major cardiovascular event. landmark cardiology trials